Premium
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California oncology group and the Japanese gastric cancer chemotherapy group
Author(s) -
Friedman Michael A.,
Ogawa Makoto,
Carter Stephen K.,
Sakurai Yoshio,
Kimura Kioji,
Hannigan John
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19831115)52:10<1771::aid-cncr2820521002>3.0.co;2-u
Subject(s) - medicine , chemotherapy , cancer , oncology , gastric adenocarcinoma , adenocarcinoma , clinical trial , randomized controlled trial
A consortium of Northern California and Japanese investigators studied 142 patients with advanced gastric adenocarcinoma. Patients were randomized to one of two combination chemotherapy programs in each nation (one common therapy shared and one therapy unique to each nation). Median duration of survial ranged between 5 and 45 weeks, depending on performance status, extent of disease, and chemotherapy program. More importantly, there was considerable comparability with respect to toxicity and outcome between patients in the US and Japan. Overall median survival was 26 weeks for Japanese and 27 weeks for US patients. This study helps provide the basis for future comparative multinational trials.